Insilico Medicine Develops and Validates Powerful AI System To Transform Drug Discovery BioSpace

The traditional drug discovery starts with the testing of thousands of small molecules in order to get to just a few lead-like molecules and only about one in ten of these molecules pass clinical trials in human patients. Insilico was able to ideate and generate a novel molecule from start to finish in 21 days. In a similar technique used by DeepMind to outcompete human GO players, GENTRL -- powered by generative chemistry that utilizes modern AI techniques -- can rapidly generate novel molecular structures with specified properties. Insilico has made GENTRL's source code available as open source. "The development of these first six molecules as an experimental validation is just the start," said Alex Zhavoronkov, CEO of Insilico Medicine.